MaxCyte is already delivering strong revenue growth, due to demand for its flow electroporation devices in drug discovery and cell therapy. This should at the very least be maintained and could accelerate if cell therapies reach the market. But the biggest potential value driver is its CARMA platform for CAR-T therapies, excitement around this new therapeutic modality has already made Kite and Juno billion dollar companies, and MaxCyte's CARMA technology could become the bedrock for next-generation CAR-T therapies. We initiate coverage of MaxCyte with a valuation of £80m, equivalent to 184p per share.
12 Jul 2016
Right here, right now: catching the CAR-T wave
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Right here, right now: catching the CAR-T wave
MaxCyte, Inc. (MXCT:LON) | 313 0 0.0% | Mkt Cap: 325.9m
- Published:
12 Jul 2016 -
Author:
Mick Cooper PhD -
Pages:
19
MaxCyte is already delivering strong revenue growth, due to demand for its flow electroporation devices in drug discovery and cell therapy. This should at the very least be maintained and could accelerate if cell therapies reach the market. But the biggest potential value driver is its CARMA platform for CAR-T therapies, excitement around this new therapeutic modality has already made Kite and Juno billion dollar companies, and MaxCyte's CARMA technology could become the bedrock for next-generation CAR-T therapies. We initiate coverage of MaxCyte with a valuation of £80m, equivalent to 184p per share.